Do GLP-1 drugs actually cause pancreatitis? Here's what the data says

What did @drnnekaanuligomd actually say?

Dr. Aniligo, a board-certified internist, claims she is seeing pancreatitis more frequently in patients on GLP-1 medications like Ozempic and Mounjaro. She describes acute pancreatitis as causing "excruciating abdominal pain" that can radiate to the back, and advises anyone on a GLP-1 experiencing severe abdominal pain to seek medical evaluation. Her core warning is practical and patient-focused.

She does not claim GLP-1 drugs definitively cause pancreatitis in most users. She frames it as a side effect she is observing more often in her own clinical practice, which is a meaningful distinction. She also stops short of telling patients to stop their medication, which is the right call. The video is largely a safety heads-up, not a fearmongering takedown of the drug class.

Does the science back this up?

Partially, yes. The FDA added a warning about pancreatitis risk to GLP-1 receptor agonist labels years ago, and the signal has been in the data since the liraglutide era. But the magnitude of the risk remains genuinely contested.

A 2022 meta-analysis by Zheng et al. in Diabetes Care found a statistically significant association between GLP-1 receptor agonists and acute pancreatitis compared to placebo, with an odds ratio around 1.78. However, a large 2016 study by Egan et al. in NEJM (the LEADER trial subgroup analysis) did not find a significant increase in pancreatitis events with liraglutide versus placebo. The evidence is not clean in either direction. Semaglutide-specific pancreatitis data from SUSTAIN and STEP trials showed low absolute event rates, making it hard to draw firm conclusions. The honest read is: the risk appears real but probably small in absolute terms, and the causal mechanism, which involves direct GLP-1 receptor activity on pancreatic acinar cells, is biologically plausible even if not proven definitively in humans.

What did they get wrong (or right)?

She got the symptom description right. Acute pancreatitis presenting with upper abdominal pain radiating to the back, plus nausea and vomiting, is textbook and accurate. Her advice to seek care for severe abdominal pain is sound and appropriate.

Where the video gets shakier is the implicit framing. By saying she is seeing this "more often" as a primary care doctor without giving any context about her patient volume or whether her GLP-1 prescribing has simply increased, she risks inflating concern beyond what the data supports. Anecdotal clinical patterns can reflect population trends, prescribing volume changes, or just confirmation bias. None of those options is wrong to raise, but she does not distinguish between them. She also does not mention that the absolute risk of pancreatitis remains low, which matters when millions of patients are weighing a drug that also reduces cardiovascular events and mortality. Omitting the baseline risk makes the warning feel bigger than the evidence suggests it should.

What should you actually know?

GLP-1 receptor agonists do carry a labeled pancreatitis warning, and patients on these drugs should know what acute pancreatitis feels like. That part of this video is genuinely useful. But context is everything here.

The absolute incidence of pancreatitis in GLP-1 clinical trials has generally been low, often under 0.5 percent in treated groups. For comparison, the background rate of acute pancreatitis in people with obesity and type 2 diabetes, the population most likely to be on these drugs, is already elevated due to gallstone risk, hypertriglyceridemia, and alcohol use. Attributing every case to the GLP-1 drug without ruling out those causes, which Dr. Aniligo actually acknowledged at the start, requires more evidence than one clinician's recent caseload. If you are on semaglutide or tirzepatide and develop severe, persistent upper abdominal pain, yes, go to an emergency room. But do not stop your medication based on this video alone. Talk to your prescriber about whether the drug is right for your specific risk profile.